INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ampio Pharmaceuticals, Inc. ("Ampio" or "the Company") AMPE for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ampio filed a Form 8-K with the SEC after regular trading hours ended on August 7, 2018. The purpose of the Form 8-K was to provide an update on the FDA's review of Ampion, and specifically the AP-003-A and AP-003-C trials. Ampio informed the market that it met with the FDA in July, 2018, and received a response letter after that meeting which stated, "as a single trial[,] the AP-003-A study alone does not appear to provide sufficient evidence of effectiveness to support [the Biologics License Application]." The FDA also stated, "the FDA does not consider the AP-003-C trial to be an adequate and well-controlled clinical trial." Based on this news, shares of Ampio fell almost 79% on August 8, 2018.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180808005891/en/